Chronic health conditions can be debilitating, and skin conditions in particular can make sufferers dread things like going to work, running errands or spending time outdoors. Millions suffer from ...
Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.
The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced. The approval of icotrokinra (Icotyde) stipulates use in adults and children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results